Top

Published in:

01-12-2012 | Review Article

Cyclin-Dependent Kinase Modulators and Cancer Therapy

Authors: Marialucia Gallorini, Amelia Cataldi, Viviana di Giacomo

Published in: BioDrugs | Issue 6/2012

Abstract

The cell cycle of eukaryotic cells varies greatly from species to species and tissue to tissue. Since an erroneous control of the cell cycle can have disastrous consequences for cellular life, there are genetically programmed signals, so-called cell cycle checkpoints, which ensure that all events of each stage are completed before beginning the next phase. Among the numerous molecules involved in this process, the most important are the cyclin-dependent kinases (CDKs), proteins that are activated only when bound to cyclins (regulatory proteins with fluctuating concentrations).

In general, more CDKs are overexpressed in cancer cells than in normal cells, which explains why cancer cells divide uncontrollably. Succeeding in modulating CDK activity with pharmacological agents could result in decreasing the abnormal proliferation rate of cancer cells.

This review offers an overview of CDK-cyclin complexes in relation to different cell cycle phases, an analysis of CDK activation and inhibition of molecular mechanisms, and an extensive report, including clinical trials, regarding four new drugs acting as CDK modulators: alvocidib, P276-00, SNS-032 and seliciclib.

Pardee AB. G₁ events and regulation of cell proliferation. Science 1989; 246: 603–8PubMedCrossRef

Morgan DO. Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev 1992; 2: 33–7PubMedCrossRef

Malumbres M, Barbacid M. To cycle or not to cycle: a decision in cancer. Nat Rev Cancer 2001; 1: 222–31PubMedCrossRef

Pines J. The cell cycle kinases. Semin Cancer Biol 1994; 5: 305–13PubMed

Obaya AJ, Sedivy JM. Regulationofcyclin-CDK activity in mammalian cells. Cell Mol Life Sci 2002; 59: 126–42PubMedCrossRef

Pines J. Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 1993; 21: 921–5PubMed

Ekholm SV, Reed SI. Regulation of G1 cyclin dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12: 676–84CrossRefPubMed

Harbour JW, Luo RX, Santi AD, et al. CDK phosphorylation triggers sequential intramolecular interactions that progressively blockRbfunctions as cells move through G₁. Cell 1999; 98: 859–69PubMedCrossRef

Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393–409PubMedCrossRef

10.

Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002; 190: 160–9PubMedCrossRef

11.

Morgan DO. Cyclin- dependent kinases: engines, clocks and microprocessors. Annu Rev Cell Dev Biol 1997; 13: 261–91PubMedCrossRef

12.

Espinoza FH, Farrell A, Erdjument-Bromage H, et al. A cyclin-dependent kinase- activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science 1996; 273: 1714–7PubMedCrossRef

13.

Fisher RP, Morgan DO. A novel cyclin associates with Mo 15/CDK7 to form the CDK- activating kinase. Cell 1994; 78: 713–24PubMedCrossRef

14.

Kaldis P, Sutton A, Solomon MJ. The CDK- activating kinase (CAK) from budding yeast. Cell 1996; 86: 553–64PubMedCrossRef

15.

De Bondt HL, Rosenblatt J, Jankarik J, et al. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363: 595–602PubMedCrossRef

16.

Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase CDK6 by the tumor suppressor p16^INK4a. Nature 1998; 395: 237–43PubMedCrossRef

17.

Fisher RP. Secret of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005; 118: 5171–80PubMedCrossRef

18.

Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994; 78: 713–24PubMedCrossRef

19.

Serizawa H, Makela TP, Conaway JW, et al. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 1995; 374: 280–2PubMedCrossRef

20.

Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-activating kinase (CAK) complex is a component of human transcription factor IIH. Nature 1995; 374: 283–7PubMedCrossRef

21.

Feaver WJ, Gileadi O, Li Y, et al. CTD kinase associated with yeast RNA polymerase II initiation factor b. Cell 1991; 67: 1223–30PubMedCrossRef

22.

Lu H, Zawel L, Fisher L, et al. Human general transcription factor IIH phos-phorylates the C-terminal domain of RNA polymerase II. Nature 1992; 358: 641–5PubMedCrossRef

23.

Serizawa H, Conaway RC, Conaway JW. A carboxyl-terminal-domain kinase associated with RNA polymerase II transcription factor delta from rat liver. Proc Natl Acad Sci U S A 1992; 89: 7476–80CrossRefPubMed

24.

Dahmus ME. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem 1996; 271: 19009–12PubMed

25.

Martinez AM, Afshar M, Martin F, et al. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity. EMBO J 1997; 16: 343–54PubMedCrossRef

26.

Garrett S, Barton WA, Knights R, et al. Reciprocal activation by cyclindependent kinases 2 and 7 is directed by substrate specificity determinants outside the T-loop. Mol Cell Biol 2001; 21: 88–99PubMedCrossRef

27.

Larochelle S, Pandur J, Fisher RP, et al. Cdk7isessential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 1998; 12: 370–81PubMedCrossRef

28.

Lolli G, Lowe ED, Brown NR, et al. The crystal structure of human CDK7 and its protein recognition properties. Structure 2004; 12: 2067–79PubMedCrossRef

29.

Wallenfang MR, Seydoux G. cdk-7 is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A 2002; 99: 5527–32PubMedCrossRef

30.

Umeda M, Shimotohno A, Yamaguchi M. Control of cell division and transcription by cyclin-dependent kinase-activating kinases in plants. Plant Cell Physiol 2005; 46: 1437–42PubMedCrossRef

31.

Adamczewski JP, Rossignol M, Tassan JP, et al. MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J 1996; 15: 1877–84PubMed

32.

Rossignol M, Kolb-Cheynel I, Egly JM. Substrate specificity of the cdkactivating kinase (CAK) is altered upon association with TFIIH. EMBO J 1997; 16: 1628–37PubMedCrossRef

33.

Yankulov KY, Bentley DL. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J 1997; 16: 1638–46PubMedCrossRef

34.

Larochelle S, Chen J, Knights R, et al. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 2001; 20: 3749–59PubMedCrossRef

35.

Grafia X, De Luca A, Sang N, et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A 1994; 91: 3834–8CrossRef

36.

Bagella L, MacLachlan TK, Buono RJ, et al. Cloning of murine Cdk9/PITALRE and its tissue-specific expression in development. J Cell Physiol 1998; 177: 206–13PubMedCrossRef

37.

Leucci E, De Falco G, Onnis A, et al. The role of the cdk9/cyclin T1complex in T cell differentiation. J Cell Physiol 2007; 212: 411–5PubMedCrossRef

38.

Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 2008; 7: 3664–8PubMedCrossRef

39.

Lin X, Taube R, Fujinaga K, et al. P-TEFb containing cyclin K and cdk9 can activate transcription via RNA. J Biol Chem 2002; 277: 16873–8PubMedCrossRef

40.

Price DH. P-TEBb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20: 2629–34PubMedCrossRef

41.

De Falco G, Giordano A. CDK9: from basal transcription to cancer and AIDS. Cancer Biol Ther 2002; 1: 342–7PubMed

42.

Shore SM, Byers SA, Maury W, et al. Identification of a novel isoform of Cdk9. Gene 2003; 307: 175–82PubMedCrossRef

43.

Shore SM, Byers SA, Dent P, et al. Characterization of Cdk9₅₅ and differential regulation of two Cdk9 isoforms. Gene 2005; 350: 51–8PubMedCrossRef

44.

De Falco G, Leucci E, Onnis A, et al. Cdk9/cyclin T1 complex: a key player during the activation/differentiation process of normal lymphoid B cells. J Cell Physiol 2008; 215: 276–82PubMedCrossRef

45.

Xiao Y, Hendriks J, Langerak P, et al. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 2004; 172: 7431–41

46.

Giacinti C, Begella L, Puri PL, et al. Myo D recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions. J Cell Physiol 2006; 206: 807–13PubMedCrossRef

47.

Iankova I, Petersen RK, Annicotte JS, et al. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol 2006; 20: 1494–505PubMedCrossRef

48.

Foskett SM, Ghose R, Tang DN, et al. Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001; 75: 1220–8PubMedCrossRef

49.

De Falco G, Bellan C, D’Amuri A, et al. Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther 2005; 4: 277–81PubMedCrossRef

50.

Napolitano G, Majello B, Licciardo P, et al. Transcriptional activity of P-TEFb kinase in vivo requires C-terminal domain of RNA polymerase II. Gene 2000; 254: 139–45PubMedCrossRef

51.

Chen R, Keating MJ, Gandhi V, et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513–9PubMedCrossRef

52.

Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800–5PubMedCrossRef

53.

Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–12PubMedCrossRef

54.

Shapiro GI. Cyclin-dependent kinase pathway as targets for cancer treatment. J Clin Oncol 2006; 11: 1770–83CrossRef

55.

Shapiro GI, Park J, Edwards CD, et al. Multiple mechanisms of p16_INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995; 55: 6200–9PubMed

56.

Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411: 1017–21PubMedCrossRef

57.

Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl 1-linked candidate oncogene. Nature 1991; 350: 512–5PubMedCrossRef

58.

Williams ME, Swerdlow SH, Meeker TC. Chromosome t(11; 14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 1993; 7: 1437–40PubMed

59.

Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–8PubMedCrossRef

60.

Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis 2001; 6: 173–82PubMedCrossRef

61.

Vandel I, Kouzarides T. Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase. EMBO J 1999; 18: 4280–91PubMedCrossRef

62.

Croxton R, Ma Y, Song L, et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21: 1359–69PubMedCrossRef

63.

Phillips A, Ernst M, Bates S, et al. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 1999; 4: 771–81PubMedCrossRef

64.

Peeper DS, Keblusek P, Helin K, et al. Phosphorylation of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro. Oncogene 1995; 10: 39–48PubMed

65.

Chen YNP, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999; 96: 4325–9PubMedCrossRef

66.

O’Connor DS, Wall NR, Porter ACG, et al. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2002; 2: 43–54PubMedCrossRef

67.

Wall NR, O’Connor DS, Plescia J, et al. Suppression of survivin phosphorylationo the 34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230–5PubMed

68.

Alonso M, Tamasdan C, Miller DC, et al. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2: 139–50PubMed

69.

Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm-2 and p21 and, independently of p53, sensitizes apoptosis reluctant cells to tumor necrosis factor. Cancer Res 2004; 64: 3653–60PubMedCrossRef

70.

Perez de Castro I, de Cancer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28: 899–912PubMedCrossRef

71.

Vizirianakis IS, Chatzopoulou M, Bonovolias ID, et al. Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. J Med Chem 2010; 53: 6779–810PubMedCrossRef

72.

Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavones that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1995; 56: 4856–61

73.

Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 eCDK4 inhuman breast carcinoma cells. Cancer Res 1996; 56: 2973–8PubMed

74.

Carlson B, Lahusen T, Singh S, et al. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999; 59: 4634–41PubMed

75.

Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376–87PubMedCrossRef

76.

Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavones L86-8275. J Natl Cancer Inst 1992; 84: 1736–40PubMedCrossRef

77.

Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007; 6: 918–25CrossRefPubMed

78.

Conroy A, Stockett DE, Walker D, et al. SNS-032 is a potent and selective CDK2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723–32PubMedCrossRef

79.

De Azevedo Jr WF, Mueller-Dieckmann HJ, Shuelze-Gahmen U, et al. Structural basis for specificity and potency of a flavopirinoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 1996; 93: 2735–40PubMedCrossRef

80.

Wright J, Blatner GL, Cheson BD. Clinical trials referral resource: clinical trials of flavopiridol. Oncology 1998; 12: 1018–24PubMed

81.

Parker B, Nieves-Neira W, Taimi M, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91: 458–65PubMed

82.

Konig A, Schwartz GK, Mohammed RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307–12PubMed

83.

Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15: 1–9PubMedCrossRef

84.

Lahusen J, Loaiza-Perez A, Sausville EA, et al. Flavopiridol-induced apoptosis is associated with p38 and MEK activation and is prevented by caspase and MAPK inhibitors. Proceedings of the Twentieth Annual Meeting of the American Association of Cancer Research; 2000 Apr 1–5; San Francisco (CA)

85.

Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. J Clin Oncol 1998; 16: 2986–99PubMed

86.

Thomas J, Cleary J, Tutsch K, et al. Phase I clinical and pharmacokinetic trial of flavopiridol. Proceedings of the eighty-eightieth Annual Meeting of the American Association of Cancer Research; 1997 Apr 12–16; San Diego (CA)

87.

Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012–8PubMedCrossRef

88.

Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin-dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22: 315–22PubMedCrossRef

89.

Grendys Jr EC, Blessing JA, Burger R, et al. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology group study. Gynecol Oncol 2005; 98: 249–53PubMedCrossRef

90.

Brusselbach S, Nettelbeck DM, Sedlacek HH, et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998; 77: 146–52PubMedCrossRef

91.

Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999; 19: 959–68PubMed

92.

Melillo G, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelian growth factor expression in human monocytes. Cancer Res 1999; 21: 5433–7

93.

Schwartz GK, O’Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20: 2157–70PubMedCrossRef

94.

Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11: 3836–45PubMedCrossRef

95.

Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005; 11: 8403–12PubMedCrossRef

96.

Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007; 13: 4467–73PubMedCrossRef

97.

Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011; 117: 3302–10PubMedCrossRef

98.

Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006; 91: 390–3PubMed

99.

Bible KC, Bible RHJ, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000; 60: 2419–28PubMed

100.

Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20: 2629–34PubMedCrossRef

101.

Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276: 31793–9PubMedCrossRef

102.

Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63: 93–9PubMed

103.

de Azevedo WFJ, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293: 566–71PubMedCrossRef

104.

Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of CDK9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011; 35: 821–30PubMedCrossRef

105.

Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma cells. Blood 2002; 100: 194–9CrossRef

106.

Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7 and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. JClin Oncol 2010; 18: 3015–22CrossRef

107.

Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113: 4637–45PubMedCrossRef

108.

Heath EI, Bible K, Martell RE, et al. A phase I study of SNS-032 (formely BMS-387032), a potent inhibitor of cyclin-dependent kinase 2, 7 and 9 administrated as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26: 59–65PubMedCrossRef

109.

Chen R, Chubb S, Cheng T, et al. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 2010; 70: 6587–97PubMedCrossRef

110.

Boquoi A, Chen T, Enders GH. Chemoprevention of mouse intestinal tumorigenesis by the CDK inhibitor SNS-032. Cancer Prev Res (Phila) 2009; 9: 800–6CrossRef

111.

Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005; 280: 31220–9PubMedCrossRef

112.

De Azevedo WF, Leclerc S, Mejier L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human Cdc2 complexed with roscovitine. Eur J Biochem 1997; 243: 518–26PubMedCrossRef

113.

Havlicek L, Hanus J, Vesely J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomucine and related compounds. J Med Chem 1997; 40: 408–12PubMedCrossRef

114.

Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280: 31208–19PubMedCrossRef

115.

Fabian MA, Biggs 3rd WH, Treiber DH, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329–36PubMedCrossRef

116.

Whittacker SR, Te Poele RH, Chan F, et al. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007; 6: 3114–31CrossRef

117.

Wesierska-Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases. Future reality or utopia? Ann N Y Acad Sci 2009; 1171: 228–41PubMedCrossRef

118.

Kim EH, Kim SU, Shin DY, et al. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004; 23: 446–56PubMedCrossRef

119.

Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclindependent kinase CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16: 1169–76PubMedCrossRef

120.

Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042–7PubMedCrossRef

121.

David-Pfeuty T. Potent inhibitors ofcyclin-dependent kinase2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 1999; 18: 7409–22PubMedCrossRef

122.

Wojciechowski J, Horky M, Guerguieva M, et al. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induce apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003; 106: 486–95PubMedCrossRef

123.

Mohapatra S, Coppola D, Riker AL, et al. Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma. Mol Cancer Res 2007; 5: 145–51PubMedCrossRef

124.

Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007; 85: 1175–86PubMedCrossRef

125.

Dey A, Wong ET, Cheok CF, et al. R-Roscovitine simultaneously targets both the p53 and NF-kappa B pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 2008; 15: 263–73PubMedCrossRef

126.

Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527–36PubMedCrossRef

127.

McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-Roscovitine). Int J Cancer 2002; 102: 463–8PubMedCrossRef

128.

Lacrima K, Lambertini C, Taborelli M, et al. In vitro activity of cyclindependent kinase inhibitor CYC202 (Seliciclib, R-Roscovitine)inmantle cell lymphoma. Ann Oncol 2005; 16: 1169–76PubMedCrossRef

129.

Mohapatra S, Chu B, Zhao X, et al. Accumulation of p53 and reduction in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65: 7717–23PubMed

130.

Rogalinska M, Blonski JZ, Komina O, et al. R-Roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J Cell Biochem 2010; 109: 217–35PubMedCrossRef

131.

Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic —pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11: 4875–87PubMedCrossRef

132.

Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitors roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60: 785–9PubMed

133.

Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclindependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administrated twice daily for 7 days every 21 days. Br J Cancer 2007; 96: 29–37PubMedCrossRef

134.

Le Tourneau C, Faivre S, Laurence V, et al. Phase Ievaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, with advances malignancies. Eur J Cancer 2010; 46: 3243–50PubMedCrossRef

135.

Maier A, Kelter G, Gianella-Borradori A. Antitumor activity of CYC202, a cyclin-dependent inhibitor, in human tumor xenografts in vitro [abstract]. Proc Am Assoc Cancer Res 2003; 44: 3119

136.

Hassan M, Sallam H, Hassan Z. The role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor — Roscovitine. Sultan Qaboos Univ Med J 2011; 11: 165–78PubMed

137.

Canellos GP. The treatment of chronic granulocytic leukemia. Clin Haematol 1977; 6: 113–28PubMed

138.

Biedler JL. Drug resistance: genotype versus phenotype. Cancer Res 1994; 54: 666–78PubMed

139.

Rowley PT. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001; 1: 245–50PubMedCrossRef

140.

Rodrigues AS, Dinis J, Gromicho M, et al. Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012; 13: 651–73PubMedCrossRef

141.

Arguello F, Alexander M, Sterry J, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 1998; 91: 2482–90PubMed

142.

Patel V, Senderowicz AM, Pinto D, et al. Flavopiridol, a novel cyclindependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102: 1674–81PubMedCrossRef

Title: Cyclin-Dependent Kinase Modulators and Cancer Therapy
Authors: Marialucia Gallorini
Amelia Cataldi
Viviana di Giacomo
Publication date: 01-12-2012
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 6/2012
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/BF03261895

At a glance: The STEP trials

Springer Medicine

Cyclin-Dependent Kinase Modulators and Cancer Therapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

The US Approach to Biosimilars

Belatacept

Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer

Acknowledgment

‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas

Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1